tirofiban has been researched along with Cardiovascular Diseases in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 6 (54.55) | 29.6817 |
2010's | 4 (36.36) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
Cao, Y; Ding, X; Gamariel, RR; Kong, Y; Li, ZY; Liu, TD; Liu, XD; Ming, X; Wang, CH; Xie, ZL; Zhao, Q | 1 |
Andreotti, F; Brancati, M; Burzotta, F; Crea, F; De Vita, M; Giammarinaro, M; Leone, AM; Mazzari, MA; Niccoli, G; Porto, I; Schiavoni, G; Talarico, GP; Todaro, D; Trani, C | 1 |
Cheng, WJ; Guo, YH; Li, YP; Liu, T; Liu, YY; Ma, HY; Shi, DM; Xie, Y; Zhao, YX; Zhou, YJ | 1 |
Biondi Zoccai, G; Bollati, M; Giraudi, E; Millesimo, G; Moretti, C; Omedè, P; Sciuto, F; Sheiban, I | 1 |
Steinhubl, SR | 1 |
Tsakiris, DA | 1 |
Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
Bauer, M; Fischer, T; Hetzer, R; Koster, A; Krabatsch, T; Kukucka, M; Kuppe, H; Meyer, O | 1 |
Kereiakes, DJ; Young, JJ | 1 |
4 trial(s) available for tirofiban and Cardiovascular Diseases
Article | Year |
---|---|
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Diabetes Complications; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardium; Necrosis; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stents; Time Factors; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2009 |
[Effects of upstream tirofiban versus downstream tirofiban on platelet aggregation and clinical outcomes in patients with high-risk acute coronary syndromes undergoing percutaneous coronary interventions].
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Thrombosis; Double-Blind Method; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIb-IX Complex; Postoperative Complications; Retreatment; Time Factors; Tirofiban; Tyrosine | 1997 |
7 other study(ies) available for tirofiban and Cardiovascular Diseases
Article | Year |
---|---|
A Naphthalenic Derivative ND-1 Inhibits Thrombus Formation by Interfering the Binding of Fibrinogen to Integrin
Topics: Abciximab; Animals; Antibodies, Monoclonal; Cardiovascular Diseases; Disease Models, Animal; Eptifibatide; Fibrinogen; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Integrin alpha2; Integrin beta3; Mice; Naphthalenes; Peptides; Platelet Aggregation; Rats; Thrombocytopenia; Thrombosis; Tirofiban; Tyrosine | 2016 |
Dual oral antiplatelet therapy and unplanned surgery: possible role for intravenous platelet glycoprotein receptor inhibitors.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Biliary Tract Surgical Procedures; Cardiovascular Diseases; Cholangitis; Choledocholithiasis; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Humans; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
The illusion of "optimal" platelet inhibition.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Blood Platelets; Cardiovascular Diseases; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Tirofiban; Tyrosine | 2012 |
[New antiaggregants and their importance for the practitioner].
Topics: Abciximab; Administration, Oral; Adult; Anesthesia, Spinal; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Contraindications; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pregnancy; Ticlopidine; Tirofiban; Tyrosine | 2003 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II.
Topics: Anticoagulants; Cardiopulmonary Bypass; Cardiovascular Diseases; Heparin; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Tirofiban; Tyrosine | 2001 |
Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Thrombosis; Cost-Benefit Analysis; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Patterns, Physicians'; Tirofiban; Tyrosine | 2002 |